← Leaderboards
Adeline Lucie Vanderver
Children'S Research Institute
$19,932,242
Attributed
$21,138,785
Total exposure
27
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,097,964 · 28
By mechanism
U54$19,255,236 · 17
U01$9,167,509 · 2
R01$1,376,840 · 1
U24$1,147,659 · 1
K08$643,090 · 1
R21$499,550 · 1
Top collaborators
- Florian S Eichler12 shared
- S. Ali Fatemi12 shared
- William Allen Gahl3 shared
- Mariko L. Bennett2 shared
- Laura Ann Adang1 shared
- Timothy R Billiar1 shared
- Robert W Grundmeier1 shared
- Qingde Wang1 shared
Most similar at Children'S Research Institute
Same institution · by research overlap
- Ljubica Morizono Caldovic$2,687,852
- Nicholas Ah Mew$1,161,811
Others in their field
Top investigators on “Leukodystrophy”
- Melissa T Forburger · American College Of Medical Genetics$7,509,634
- Albee Messing · University Of Wisconsin Madison$6,787,126
- Paul Joseph Tesar · Case Western Reserve University$6,174,793
- Mark S Sands · Washington University$6,092,843
- Melissa Pittel Wasserstein · Icahn School Of Medicine At Mount Sinai$6,083,557
- Quasar S Padiath · University Of Pittsburgh At Pittsburgh$5,958,511
Research focus
LeukodystrophyAffectClinical Trials NetworkAdvocacyClinical TrialsFutureNatural HistoryCommunitiesRare DiseasesPatient Outcomes AssessmentsDiagnosisClinical Trial ReadinessPseudotoxoplasmosis SyndromeIndustry PartnerCaringMyelinBaseResearch PersonnelLettersBrainGenesCollaborationsProgramsPhenotype
Grant awards (68)
Global Leukodystrophy Initiative Clinical Trials Network (GLIA- CTN)$1,753,747
U54 · FY2025 · NS · contact PI
Interactions Between Diverse Brain Cell Types Drive Aicardi-Goutieres Neuropathology$675,062
R01 · FY2025 · NS
Project 1: Longitudinal Natural History Studies of Leukodystrophies$650,777
U54 · FY2025 · NS · contact PI
Administrative Component of the Global Leukodystrophy Initiative Clinical Trials Unit (GLIA-CTN)$465,191
U54 · FY2025 · NS · contact PI
GLIA-CTN Genomic Expert Curation Panel$359,546
U24 · FY2025 · NS · contact PI
Pilot Core of the Global Leukodystrophy Initiative Clinical Trial Network (GLIA-CTN)$51,798
U54 · FY2025 · NS · contact PI
Global Leukodystrophy Initiative Clinical Trials Network Gap Year Administrative Supplement$1,009,720
U54 · FY2024 · NS · contact PI
Interactions between diverse brain cell types drive Aicardi-Goutieres neuropathology$701,778
R01 · FY2024 · NS
GLIA-CTN Genomic Expert Curation Panel$370,485
U24 · FY2024 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,377,421
U54 · FY2023 · NS · contact PI
: Clinical Outcomes in Aicardi Goutières Syndrome$1,144,269
U01 · FY2023 · NS · contact PI
Optimizing Trial Readiness for Adrenomyeloneuropathy$637,158
U54 · FY2023 · NS · contact PI
Administrative Unit for the GLIA-CTN$511,971
U54 · FY2023 · NS · contact PI
ALD Healthy Planet Project$511,971
U54 · FY2023 · NS · contact PI
GLIA-CTN Genomic Expert Curation Panel$417,628
U24 · FY2023 · NS · contact PI
Administrative Unit for the GLIA-CTN$202,572
U54 · FY2023 · NS · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$165,510
U54 · FY2023 · NS · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$143,448
U54 · FY2023 · NS · contact PI
Myelin Disorders Biorepository Project (MDBP) at the Biospecimen Exchange for Neurological Disorders (BioSEND)$143,448
U54 · FY2023 · NS · contact PI
Career Enhancement Core of GLIA-CTN$127,610
U54 · FY2023 · NS · contact PI
Improved clinical and biologic outcome measures in Aicardi Goutieres Syndrome$124,947
U54 · FY2023 · NS · contact PI
Validation of the GMFC-MLD$67,640
U54 · FY2023 · NS · contact PI
: Clinical Outcomes in Aicardi Goutières Syndrome$1,440,627
U01 · FY2022 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,397,307
U54 · FY2022 · NS · contact PI
Optimizing Trial Readiness for Adrenomyeloneuropathy$625,515
U54 · FY2022 · NS · contact PI
Reverse transcriptase inhibition as a novel therapeutic approach for ADAR-1-related Aicardi Goutières Syndrome$499,550
R21 · FY2022 · NS · contact PI
Administrative Unit for the GLIA-CTN$184,287
U54 · FY2022 · NS · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$165,563
U54 · FY2022 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$137,700
U54 · FY2022 · NS · contact PI
Career Enhancement Core of GLIA-CTN$137,700
U54 · FY2022 · NS · contact PI
Career Enhancement Core of GLIA-CTN$124,226
U54 · FY2022 · NS · contact PI
Improved clinical and biologic outcome measures in Aicardi Goutieres Syndrome$121,633
U54 · FY2022 · NS · contact PI
Clinical Outcomes in Aicardi Goutières Syndrome$1,632,098
U01 · FY2021 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,405,684
U54 · FY2021 · NS · contact PI
Optimizing Trial Readiness for Adrenomyeloneuropathy$630,613
U54 · FY2021 · NS · contact PI
Administrative Unit for the GLIA-CTN$186,777
U54 · FY2021 · NS · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$165,595
U54 · FY2021 · NS · contact PI
Utility of advanced MRI and wearable technology to identify sensory motor outcome measures in leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL)$156,700
U54 · FY2021 · NS · contact PI
Career Enhancement Core of GLIA-CTN$124,458
U54 · FY2021 · NS · contact PI
Improved clinical and biologic outcome measures in Aicardi Goutieres Syndrome$121,861
U54 · FY2021 · NS · contact PI
Clinical Outcomes in Aicardi GoutiÃÂÃÂÃÂères Syndrome$1,462,876
U01 · FY2020 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,414,956
U54 · FY2020 · NS · contact PI
Optimizing Trial Readiness for Adrenomyeloneuropathy$634,715
U54 · FY2020 · NS · contact PI
Administrative Unit for the GLIA-CTN$190,003
U54 · FY2020 · NS · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$165,771
U54 · FY2020 · NS · contact PI
Career Enhancement Core of GLIA-CTN$124,239
U54 · FY2020 · NS · contact PI
Improved clinical and biologic outcome measures in Aicardi Goutieres Syndrome$121,646
U54 · FY2020 · NS · contact PI
Clinical Outcomes in Aicardi Goutières Syndrome$1,867,066
U01 · FY2019 · NS · contact PI
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)$1,582,885
U54 · FY2019 · NS · contact PI
Optimizing Trial Readiness for Adrenomyeloneuropathy$661,114
U54 · FY2019 · TR · contact PI
Administrative Unit for the GLIA-CTN$226,748
U54 · FY2019 · TR · contact PI
Improved Outcome Assessments in Adrenomyeloneuropathy$206,533
U54 · FY2019 · TR · contact PI
Career Enhancement Core of GLIA-CTN$149,600
U54 · FY2019 · TR · contact PI
Improved clinical and biologic outcome measures in Aicardi Goutieres Syndrome$146,478
U54 · FY2019 · TR · contact PI
Reverse Transcriptase Inhibitors in Aicardi Goutieres Syndrome$1,043,273
U01 · FY2018 · HD · contact PI
Reverse Transcriptase Inhibitors in Aicardi Goutieres Syndrome$164,280
U01 · FY2017 · HD · contact PI
Antiretroviral Therapy in Aicardi Goutieres Syndrome$125,001
U01 · FY2016 · HD · contact PI
Antiretroviral Therapy in Aicardi Goutieres Syndrome$288,019
U01 · FY2015 · HD · contact PI
Molecular Mechanisms in Vanishing White Matter Disease$138,298
K08 · FY2013 · NS · contact PI
Molecular Mechanisms in Vanishing White Matter Disease$126,198
K08 · FY2012 · NS · contact PI
Molecular Mechanisms in Vanishing White Matter Disease$126,198
K08 · FY2011 · NS · contact PI
Molecular Mechanisms in Vanishing White Matter Disease$126,198
K08 · FY2010 · NS · contact PI
Molecular Mechanisms in Vanishing White Matter Disease$126,198
K08 · FY2009 · NS · contact PI
NEW DIAGNOSTIC APPROACHES IN LEUKODYSTROPHY$2,738
M01 · FY2008 · RR · contact PI
IMPROVED DIAGNOSIS OF UNCLASSIFIED LEUKODYSTROPHIES$1,370
M01 · FY2008 · RR · contact PI
NEW DIAGNOSTIC APPROACHES IN LEUKODYSTROPHY$1,271
M01 · FY2007 · RR · contact PI
IMPROVED DIAGNOSIS OF UNCLASSIFIED LEUKODYSTROPHIES$636
M01 · FY2007 · RR · contact PI
IMPROVED DIAGNOSIS OF UNCLASSIFIED LEUKODYSTROPHIES$2,065
M01 · FY2006 · RR · contact PI